With the increasing popularity of GLP-1 drugs such as Wegovy and Ozempic, there is a growing anticipation for oral versions of these medications. Recent positive results from Eli Lilly's oral GLP-1 drug orforglipron in Phase 3 trials reinforce this trend. Moreover, the FDA's acceptance of Novo Nordisk's Wegovy pill application brings optimism for accessibility. However, not all development has succeeded, illustrated by Pfizer's decision to abandon danuglipron due to safety concerns. Experts suggest that while oral versions may become widespread, injectables will still have a significant market appeal due to user preferences.
As GLP-1 drugs like Wegovy and Ozempic become more popular, it's easy to imagine a near future where a version of them that can be taken orally would become even more widespread.
Laura Hensley pointed out another reason why a pill form could be more popular than their injectable counterparts: the lack of a need for refrigeration.
Collection
[
|
...
]